Evogene Ltd.
| NASDAQ: EVGN | Healthcare / Biotechnology / Israel |
| 0.8401 | -0.0008 | -0.10% | Vol 323.28K | 1Y Perf 35.63% |
| Dec 6th, 2023 15:58 DELAYED |
| BID | 0.8400 | ASK | 0.8504 | ||
| Open | 0.8221 | Previous Close | 0.8409 | ||
| Pre-Market | - | After-Market | 0.81 | ||
| - - | -0.03 -3.56% |
| Target Price | 5.33 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 534.45 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 49.77 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 44.87 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 39.39 | Earnings Rating | Strong Sell | |
| Market Cap | 34.65M | Earnings Date | 15th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.26 | |
| Beta | 1.49 |
Today's Price Range 0.82210.8600 | 52W Range 0.45021.44 | 5 Year PE Ratio Range -3.50-3.20 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 26.41% | ||
| 1 Month | 41.02% | ||
| 3 Months | 9.29% | ||
| 6 Months | 45.74% | ||
| 1 Year | 35.63% | ||
| 3 Years | -78.33% | ||
| 5 Years | -64.22% | ||
| 10 Years | -95.39% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -24.00 | |||
ROE last 12 Months | -75.64 | |||
ROA (5Y Avg) | -17.12 | |||
ROA last 12 Months | -47.70 | |||
ROC (5Y Avg) | -31.83 | |||
ROC last 12 Months | -55.43 | |||
Return on invested Capital Q | -15.95 | |||
Return on invested Capital Y | -12.41 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.00 | ||||
| 1.01 | ||||
| 30.45 | ||||
| 81.70 | ||||
| -1.40 | ||||
| -0.72 | ||||
| 1.01 | ||||
| 0.74 | ||||
| 4.11M | ||||
| Forward PE | -2.38 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.30 | ||||
| 7.30 | ||||
| 0.27 | ||||
| 0.39 | ||||
| -11.50 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 38.80 | ||||
| -2 363.00 | ||||
| -2 175.10 | ||||
| -1 891.80 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.02M | ||||
| 0.02 | ||||
| -22.23 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.17 | -0.08 | 52.94 |
| Q02 2023 | -0.19 | -0.17 | 10.53 |
| Q01 2023 | -0.16 | -0.15 | 6.25 |
| Q04 2022 | -0.21 | -0.07 | 66.67 |
| Q03 2022 | -0.20 | -0.16 | 20.00 |
| Q02 2022 | -0.18 | -0.21 | -16.67 |
| Q01 2022 | -0.14 | -0.20 | -42.86 |
| Q04 2021 | -0.20 | -0.18 | 10.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.14 | -55.56 | Negative |
| 12/2023 FY | -0.47 | 6.00 | Positive |
| 3/2024 QR | -0.07 | 36.36 | Positive |
| 12/2024 FY | -0.29 | 17.14 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.17 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 323.28K |
| Shares Outstanding | 50.55K |
| Shares Float | 38.72M |
| Trades Count | 675 |
| Dollar Volume | 273.17K |
| Avg. Volume | 151.31K |
| Avg. Weekly Volume | 219.32K |
| Avg. Monthly Volume | 113.77K |
| Avg. Quarterly Volume | 120.86K |
Evogene Ltd. (NASDAQ: EVGN) stock closed at 0.8409 per share at the end of the most recent trading day (a 15.19% change compared to the prior day closing price) with a volume of 415.57K shares and market capitalization of 42.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 139 people. Evogene Ltd. CEO is Ofer Haviv.
The one-year performance of Evogene Ltd. stock is 35.63%, while year-to-date (YTD) performance is 20.13%. EVGN stock has a five-year performance of -64.22%. Its 52-week range is between 0.4502 and 1.44, which gives EVGN stock a 52-week price range ratio of 39.39%
Evogene Ltd. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 1.01, a price-to-sale (PS) ratio of 30.45, a price to cashflow ratio of 81.70, a PEG ratio of -, a ROA of -47.70%, a ROC of -55.43% and a ROE of -75.64%. The company’s profit margin is -%, its EBITDA margin is -2 175.10%, and its revenue ttm is $1.02 Million , which makes it $0.02 revenue per share.
Of the last four earnings reports from Evogene Ltd., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Evogene Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Evogene Ltd. is Strong Buy (1), with a target price of $5.33, which is +534.45% compared to the current price. The earnings rating for Evogene Ltd. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evogene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evogene Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.93, ATR14 : 0.06, CCI20 : 272.69, Chaikin Money Flow : 0.34, MACD : 0.04, Money Flow Index : 76.20, ROC : 26.26, RSI : 74.06, STOCH (14,3) : 96.96, STOCH RSI : 1.00, UO : 66.83, Williams %R : -3.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evogene Ltd. in the last 12-months were:
Evogene Ltd.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
CEO: Ofer Haviv
Telephone: +972 89311900
Address: 13 Gad Feinstein Street, Rehovot 7612002, , IL
Number of employees: 139
TipRanks News for EVGN
Thu, 17 Aug 2023 17:35 GMT Evogene (EVGN) Receives a Buy from Lake Street
- TipRanks. All rights reserved.
